Olanzapine: Effective Management of Schizophrenia and Bipolar Disorder
| Product dosage: 2.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.74 | $44.18 (0%) | 🛒 Add to cart |
| 90 | $0.71 | $66.27 $64.26 (3%) | 🛒 Add to cart |
| 120 | $0.69 | $88.36 $83.34 (6%) | 🛒 Add to cart |
| 180 | $0.69 | $132.54 $123.50 (7%) | 🛒 Add to cart |
| 270 | $0.68 | $198.80 $182.74 (8%) | 🛒 Add to cart |
| 360 | $0.67
Best per pill | $265.07 $241.98 (9%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $1.00 | $60.24 (0%) | 🛒 Add to cart |
| 90 | $0.96 | $90.36 $86.35 (4%) | 🛒 Add to cart |
| 120 | $0.95 | $120.49 $113.46 (6%) | 🛒 Add to cart |
| 180 | $0.93 | $180.73 $166.67 (8%) | 🛒 Add to cart |
| 270 | $0.91 | $271.09 $245.99 (9%) | 🛒 Add to cart |
| 360 | $0.90
Best per pill | $361.46 $325.31 (10%) | 🛒 Add to cart |
| Product dosage: 7.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.44 | $43.17 (0%) | 🛒 Add to cart |
| 60 | $1.32 | $86.35 $79.32 (8%) | 🛒 Add to cart |
| 90 | $1.29 | $129.52 $116.47 (10%) | 🛒 Add to cart |
| 120 | $1.28 | $172.70 $153.62 (11%) | 🛒 Add to cart |
| 180 | $1.26 | $259.05 $226.92 (12%) | 🛒 Add to cart |
| 270 | $1.25 | $388.57 $337.36 (13%) | 🛒 Add to cart |
| 360 | $1.25
Best per pill | $518.09 $448.81 (13%) | 🛒 Add to cart |
Synonyms | |||
Olanzapine is an atypical antipsychotic medication widely prescribed for the treatment of schizophrenia and bipolar I disorder. It functions primarily by antagonizing dopamine and serotonin receptors in the brain, which helps to restore neurotransmitter balance and alleviate symptoms of psychosis and mood instability. Clinically proven to reduce positive and negative symptoms in schizophrenia and to manage acute manic or mixed episodes in bipolar disorder, olanzapine offers a robust therapeutic option for patients requiring long-term psychotropic care. Its efficacy, coupled with a generally tolerable side effect profile, makes it a cornerstone in modern psychiatric pharmacotherapy.
Features
- Active ingredient: Olanzapine
- Available formulations: Oral tablets, orally disintegrating tablets, and intramuscular injection
- Standard tablet strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg
- Mechanism of action: Dopamine D2 and serotonin 5-HT2A receptor antagonist
- Half-life: Approximately 21–54 hours
- Bioavailability: ~60% following oral administration
- Protein binding: ~93%
- Metabolism: Hepatic, primarily via CYP1A2 and glucuronidation
- Excretion: Urine (57%) and feces (30%)
Benefits
- Rapid reduction of acute psychotic symptoms such as hallucinations, delusions, and disorganized thinking
- Effective stabilization of mood episodes in bipolar disorder, including manic and mixed states
- Improvement in negative symptoms of schizophrenia, including social withdrawal and apathy
- Lower risk of extrapyramidal symptoms compared to typical antipsychotics
- Flexible dosing and formulation options to accommodate individual patient needs and adherence
- Long half-life supports once-daily dosing, improving compliance
Common use
Olanzapine is indicated for the treatment of schizophrenia in adults and adolescents aged 13 years and older. It is also approved for acute monotherapy or adjunctive therapy in bipolar I disorder for manic or mixed episodes, and for maintenance treatment in bipolar I disorder. Off-label uses may include treatment of agitation associated with dementia (though with caution due to increased mortality risk in elderly patients with dementia-related psychosis), Tourette syndrome, and as an adjunct in treatment-resistant depression.
Dosage and direction
Dosage must be individualized based on clinical condition, response, and tolerability. For schizophrenia in adults, the recommended starting dose is 5–10 mg once daily, with a target range of 10–20 mg/day. For bipolar mania, initial dosing is 10–15 mg once daily. Dosage adjustments should occur at intervals not less than 24 hours. For geriatric patients or those with hepatic impairment, a lower starting dose (5 mg) is recommended. Administration is oral, with or without food. Orally disintegrating tablets should be placed on the tongue and allowed to dissolve. Intramuscular injection is reserved for acute agitation in schizophrenia or bipolar mania, with doses of 2.5–10 mg, repeated as needed (maximum 30 mg/24 hours).
Precautions
Olanzapine use requires careful monitoring due to potential metabolic, neurologic, and cardiovascular effects. Regular assessment of weight, blood glucose, and lipid profiles is advised. Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death. Use with caution in patients with conditions that predispose to hypotension, seizures, or dysphagia. Neuroleptic malignant syndrome (NMS) and tardive dyskinesia (TD) are potential risks. Patients should avoid alcohol and activities requiring mental alertness until response is known. Olanzapine may cause hyperprolactinemia, which should be monitored if clinically indicated.
Contraindications
Olanzapine is contraindicated in patients with known hypersensitivity to olanzapine or any component of the formulation. It should not be used in patients with narrow-angle glaucoma. Concurrent use with other central nervous system depressants (e.g., opioids, benzodiazepines) requires extreme caution due to additive effects. Olanzapine is not approved for use in patients with dementia-related psychosis due to increased mortality risk.
Possible side effect
Common side effects include somnolence, weight gain, dizziness, increased appetite, and peripheral edema. Elevated prolactin, orthostatic hypotension, and dry mouth may occur. Less frequently, patients may experience extrapyramidal symptoms, hyperglycemia, dyslipidemia, or transaminase elevations. Rare but serious adverse effects include neuroleptic malignant syndrome, tardive dyskinesia, seizures, and leukopenia/neutropenia. Injection-site reactions may occur with intramuscular administration.
Drug interaction
Olanzapine is metabolized by CYP1A2; concomitant use with CYP1A2 inhibitors (e.g., fluvoxamine) may increase olanzapine concentrations. Inducers of CYP1A2 (e.g., carbamazepine, omeprazole, smoking) may decrease olanzapine levels. Use with other centrally acting drugs (e.g., benzodiazepines, antihypertensives) may potentiate sedation and hypotension. Anticholinergic effects may be enhanced with other anticholinergic drugs. Olanzapine may antagonize the effects of levodopa and dopamine agonists. Caution is advised with drugs that prolong QT interval, though olanzapine itself has a minimal effect.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is close to the time of the next dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling up on doses is not recommended.
Overdose
Symptoms of olanzapine overdose may include drowsiness, slurred speech, tachycardia, hypotension, and extrapyramidal symptoms. In severe cases, delirium, coma, or respiratory depression may occur. There is no specific antidote; management is supportive and includes gastric lavage (if presented early), activated charcoal, and monitoring of vital signs. Cardiovascular support may be necessary. Consider ECG monitoring due to potential QT prolongation.
Storage
Store at controlled room temperature (20–25°C or 68–77°F); excursions permitted to 15–30°C (59–86°F). Protect from light and moisture. Keep out of reach of children and pets. Do not use if packaging is compromised or after the expiration date.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Do not disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
Clinical trials and post-marketing surveillance demonstrate olanzapine’s efficacy in reducing psychotic and manic symptoms, with many patients experiencing significant improvement in quality of life. However, weight gain and metabolic changes are frequently noted drawbacks. Long-term studies support its use in maintenance therapy, though regular monitoring is essential. Patient experiences vary; some report substantial symptom relief with manageable side effects, while others discontinue due to metabolic concerns or sedation.